Zhou Tao, Ando Takayuki, Kudo Akihiro, Sato Michio, Miyoshi Noriyuki, Mutoh Michihiro, Ishikawa Hideki, Wakabayashi Keiji, Watanabe Kenji
Adenoprevent Co., Ltd., Shizuoka, 422-8526, Japan.
Department of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, 422-8526, Japan.
Genes Environ. 2023 Feb 16;45(1):8. doi: 10.1186/s41021-023-00264-7.
Colibactin is a genotoxin produced by Escherichia coli and other Enterobacteriaceae that is believed to increase the risk of colorectal cancer (CRC) of their symbiosis hosts, including human. A peptidase ClbP is the key enzyme for activation of colibactin. Inhibition of ClbP is considered to impede maturation of precolibactin into genotoxic colibactin. Therefore, ClbP-specific inhibitors could potentially prevent the onset of CRC, one of the leading causes of cancer-related deaths in the world. This study intends to establish an efficient screening system for identifying inhibitors that are specific to ClbP.
Two types of assays were applied in the screening procedure: a probe assay and an LC-MS assay. For the probe assay, we employed the synthesized probe which we described in our previous report. This probe can be hydrolyzed efficiently by ClbP to release a fluorophore. Hence it was applied here for detection of inhibition of ClbP. For the LC-MS assay, formation of the byproduct of precolibactin maturation process, N-myristoyl-D-asparagine, was quantified using a liquid chromatography-mass spectrometry (LC-MS) technique. The probe assay can be performed much faster, while the LC-MS assay is more accurate. Therefore, our method employed the two assays in sequence to screen a large number of compounds for inhibition of ClbP.
A library of 67,965 standard compounds was evaluated by the screening method established in the current study, and one compound was found to show a moderate inhibitory activity against ClbP.
A simple screening method for ClbP-specific inhibitors was established. It was proven to be reliable and is believed to be useful in developing potential prophylactic agents for CRC.
大肠杆菌素是由大肠杆菌和其他肠杆菌科细菌产生的一种基因毒素,据信会增加其共生宿主(包括人类)患结直肠癌(CRC)的风险。肽酶ClbP是激活大肠杆菌素的关键酶。抑制ClbP被认为会阻碍前体大肠杆菌素成熟为具有基因毒性的大肠杆菌素。因此,ClbP特异性抑制剂有可能预防CRC的发生,CRC是全球癌症相关死亡的主要原因之一。本研究旨在建立一种高效的筛选系统,以鉴定对ClbP具有特异性的抑制剂。
在筛选过程中应用了两种类型的检测方法:探针检测法和液相色谱-质谱(LC-MS)检测法。对于探针检测法,我们使用了我们之前报告中描述的合成探针。该探针可被ClbP有效水解以释放荧光团。因此,它在此处用于检测ClbP的抑制作用。对于LC-MS检测法,使用液相色谱-质谱(LC-MS)技术对前体大肠杆菌素成熟过程的副产物N-肉豆蔻酰-D-天冬酰胺的形成进行定量。探针检测法可以更快地进行,而LC-MS检测法更准确。因此,我们的方法依次使用这两种检测方法来筛选大量抑制ClbP的化合物。
通过本研究建立的筛选方法对一个包含67,965种标准化合物的文库进行了评估,发现一种化合物对ClbP表现出中等抑制活性。
建立了一种针对ClbP特异性抑制剂的简单筛选方法。已证明该方法可靠,并且有望用于开发潜在的CRC预防药物。